TG Therapeutics say-on-pay fails at 2026 annual meeting; directors elected

Proposal 1 The votes with respect to the election of the six directors to hold office until the 2027 annual meeting were as follows: Director Votes For % Voted For Votes Withheld % Voted Withheld Broker Non-Votes Michael S. Weiss 72,172,630 88.63% 9,260,279 11.37% 31,570,505 Laurence N. Charney 68,135,448 83.67% 13,297,461 16.33% 31,570,505 Yann Echelard 64,110,661 78.73% 17,322,248 21.27% 31,570,505 Kenneth Hoberman 53,354,717 65.52% 28,078,192 34.48% 31,570,505 Daniel Hume 63,979,535 78.57% 17,453,374 21.43% 31,570,505 Sagar Lonial, MD 44,666,544 54.85% 36,766,365 45.15% 31,570,505

Proposal 3 The advisory vote to approve the compensation of the Company’s named executive officers was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 31,905,837 48,858,169 668,903 31,570,505

Proposal 2 The vote with respect to the ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was as follows: Total Votes For Total Votes Against Abstentions Broker Non-Votes 112,329,330 531,758 142,326 --